NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its second quarter 2024 financial results on Monday, August 12, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conferen ...

NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its second quarter 2024 financial results on Monday, August 12, 2024, after the market closes. Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conferen ...

-- Inclusion of the top neurorehabilitation centers REHABOLOGYM, Neurology Center of New England, and MGH Institute of Health Professions completes site participation enrollment for the U.S. registrational program in stroke -- "PoNS Therapy has demonstrated the ability to generate neuroplasticity, essentially rewiring parts of the brain to significantly and meaningfully improve gait and balance in chronic stroke survivors. With the addition of REHABOLOGYM, NCNE, and MGH-IHP, we now have five of the top neur ...

The registrational program was established in part based on real-world evidence from Canada, where PoNS is already authorized for treatment of stroke. To support national reimbursement in Canada, Helius has begun an additional study on the use of PoNS Therapy to treat stroke, with the goal of enrolling 60 subjects by the end of 2024 at three centers of excellence for stroke rehabilitation. The study led by Dr. Murielle Grangeon, PhD, Adm., Founder and General Manager, at Neuro-Concept Rehabilitation Center, ...

-- Reimbursement at $23,900, slightly below list price -- -- Represents a significant milestone toward increasing accessibility of PoNS -- NEWTOWN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the first third-party reimbursement from a major insurance carrier for the Company's Portable Neuromodulation Stimu ...

NEWTOWN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, will exhibit for the third consecutive year at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, where it will spotlight a year of significant progress in making its innovative Portable Neuromodulation Stimulator (PoNS®) more accessible to people whos ...

NEWTOWN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, will exhibit for the third consecutive year at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, where it will spotlight a year of significant progress in making its innovative Portable Neuromodulation Stimulator (PoNS®) more accessible to people whos ...

Core Insights - Helius Medical Technologies has received approval for its Portable Neuromodulation Stimulator (PoNS®) device to be included in the Veterans Affairs (VA) Federal Supply Schedule and GSA Advantage contracts, providing access to U.S. veterans and government employees suffering from gait and balance impairments due to multiple sclerosis (MS) [1][4] Product and Pricing - The PoNS system is priced at $23,843.72, while the PoNS mouthpiece costs $7,344.97, and it is indicated for short-term treatment of gait deficits in adults with mild-to-moderate MS symptoms when used alongside physical therapy [2] - The device is designed to deliver neurostimulation through a mouthpiece and is primarily used at home in conjunction with physical rehabilitation exercises [7] Market Potential - The VA estimates that between 55,000 and 70,000 veterans in the U.S. are living with MS, indicating a significant potential market for the PoNS device [3] - The inclusion of PoNS on the FSS Med/Surg and GSA Advantage marketplace is expected to facilitate quicker access to this therapy for veterans and federal employees [4] Company Background - Helius Medical Technologies focuses on neurologic deficits and aims to improve the lives of individuals dealing with neurologic diseases through its innovative technology platform [6] - Lovell Government Services, a partner of Helius, has a strong track record in introducing suppliers to the government market and aims to enhance federal revenue streams for medical and pharmaceutical companies [5]

Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q1 2024 Results Conference Call May 13, 2024 4:30 PM ET Company Participants Michelle Bilski - Investor Relations-In-Site Communications Dane Andreeff - President and Chief Executive Officer Jeff Mathiesen - Chief Financial Officer Conference Call Participants Nicholas Sherwood - Maxim Group Operator Good day, and thank you for standing by. Welcome to the Helius Medical Technologies First Quarter 2024 Earnings Conference Call. At this time, all participants ar ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38445 HELIUS MEDICAL TECHNOLOGIES, INC. (Exact name of Registrant as specified in its charter) | Delaware | 36-4787690 | | - ...